Cargando…

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells

Prostate cancer (PCa) is a common malignant disease with high mortality rates that develops and progresses in an androgen-dependent way. In recent years, RNA sequencing enabled identification of many PCa-related long non- coding RNAs including androgen receptor-regulated long non-coding RNA 1 (ARLNC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huseynova, Günel, Özgür, Emre, Bilgiç Gazioğlu, Sema, Esin Yörüker, Ebru, Gezer, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royan Institute 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790070/ https://www.ncbi.nlm.nih.gov/pubmed/36527350 http://dx.doi.org/10.22074/CELLJ.2022.557563.1076

Ejemplares similares

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression
por: Zhang, Yajia, et al.
Publicado: (2018)

MicroRNA Expression Profiles in Papillary Thyroid Carcinoma, Benign Thyroid Nodules and Healthy Controls
por: Yoruker, Ebru Esin, et al.
Publicado: (2016)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML)
por: Zhao, Chunxia, et al.
Publicado: (2021)

Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer
por: Gezer, Ugur, et al.
Publicado: (2015)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells
por: Gezer, Ugur, et al.
Publicado: (2015)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
por: Toren, Paul, et al.
Publicado: (2016)

Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms
por: Cetin, Turan, et al.
Publicado: (2012)

Promoter and histone methylation and p16(INK4A) gene expression in colon cancer
por: YORUKER, EBRU ESIN, et al.
Publicado: (2012)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
por: Sugimoto, Mikio, et al.
Publicado: (2022)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
por: Banuelos, Carmen A., et al.
Publicado: (2020)

Role of maximum androgen blockade in advanced prostate cancer
por: Ayyathurai, Rajinikanth, et al.
Publicado: (2009)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022)

Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast Cancer
por: Özgür, Emre, et al.
Publicado: (2022)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
por: Iguchi, Taro, et al.
Publicado: (2019)

Elevated plasma concentrations of S100 calcium-binding protein B and tumor necrosis factor alpha in children with autism spectrum disorders
por: Guloksuz, Selin Aktan, et al.
Publicado: (2017)

Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death
por: Xiang, Zhendong, et al.
Publicado: (2021)

Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor
por: Wang, Bi-Juan, et al.
Publicado: (2022)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression()
por: Li, Zhenghong, et al.
Publicado: (2020)

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide
por: Pilling, Amanda B., et al.
Publicado: (2019)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease
por: Işın, Mustafa, et al.
Publicado: (2015)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
por: Sun, Wei, et al.
Publicado: (2019)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression
por: Zhang, Meng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_21v6p1ohalbr12ku4ju6ludb3u